Literature DB >> 32795556

NLRP3 Inflammasomes in Parkinson's disease and their Regulation by Parkin.

Yi-Qun Yan1, Yi Fang1, Ran Zheng1, Jia-Li Pu2, Bao-Rong Zhang3.   

Abstract

Chronic inflammation might correlate with the formation of α-synuclein oligomers, subsequently leading to dopaminergic (DA) neuronal death in Parkinson's disease (PD). As major components of chronic inflammation, NOD-like receptor protein 3 (NLRP3) inflammasomes play a crucial role in PD via caspase 1 activation, primarily induced by mitochondrial damage. NLRP3 binds to apoptosis-associated speck-like protein containing a CARD (PYCARD/ASC), and forms inflammasomes in the brain. Inflammasomes act as a platform for caspase 1 to induce interleukin 1 Beta (IL1β) maturation, leading to neuronal pyroptosis. Furthermore, alpha-synuclein, whose abnormal aggregation is the main pathogenesis of PD, also activates NLRP3 inflammasomes. Mutations to PRKN (encoding Parkin) are the most common cause of autosomal recessive familial and sporadic early-onset PD. Evidence has confirmed a relationship between Parkin and NLRP3 inflammasomes. In this review, we summarize the current understanding of NLRP3 inflammasomes and their role in PD progression, and discuss their regulation by Parkin.
Copyright © 2020 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  NLRP3 inflammasome; Parkin; Parkinson’s disease; α-synuclein

Mesh:

Substances:

Year:  2020        PMID: 32795556     DOI: 10.1016/j.neuroscience.2020.08.004

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  11 in total

1.  VRT-043198 Ameliorates Surgery-Induced Neurocognitive Disorders by Restoring the NGF and BNDF Expression in Aged Mice.

Authors:  Qi Tang; Qiang Guo; Ke Li; Fan Fei
Journal:  Neuropsychiatr Dis Treat       Date:  2022-05-16       Impact factor: 2.989

Review 2.  Parkinson's Disease and SARS-CoV-2 Infection: Particularities of Molecular and Cellular Mechanisms Regarding Pathogenesis and Treatment.

Authors:  Aurelian Anghelescu; Gelu Onose; Cristina Popescu; Mihai Băilă; Simona Isabelle Stoica; Ruxandra Postoiu; Elena Brumă; Irina Raluca Petcu; Vlad Ciobanu; Constantin Munteanu
Journal:  Biomedicines       Date:  2022-04-26

Review 3.  Pathophysiological Clues to How the Emergent SARS-CoV-2 Can Potentially Increase the Susceptibility to Neurodegeneration.

Authors:  Mahsa Dolatshahi; Mohammadmahdi Sabahi; Mohammad Hadi Aarabi
Journal:  Mol Neurobiol       Date:  2021-01-08       Impact factor: 5.590

4.  Bibliometric Analysis of the Inflammasome and Pyroptosis in Brain.

Authors:  Yuhua Chen; Yan Li; Limin Guo; Jun Hong; Wenjuan Zhao; Ximin Hu; Cuicui Chang; Wei Liu; Kun Xiong
Journal:  Front Pharmacol       Date:  2021-01-20       Impact factor: 5.810

Review 5.  NLRP3 Inflammasome Pharmacological Inhibitors in Glycyrrhiza for NLRP3-Driven Diseases Treatment: Extinguishing the Fire of Inflammation.

Authors:  Zhilei Wang; Guang Xu; Zhiyong Li; Xiaohe Xiao; Jianyuan Tang; Zhaofang Bai
Journal:  J Inflamm Res       Date:  2022-01-19

6.  iPSC-Derived Microglia as a Model to Study Inflammation in Idiopathic Parkinson's Disease.

Authors:  Katja Badanjak; Patrycja Mulica; Semra Smajic; Sylvie Delcambre; Leon-Charles Tranchevent; Nico Diederich; Thomas Rauen; Jens C Schwamborn; Enrico Glaab; Sally A Cowley; Paul M A Antony; Sandro L Pereira; Carmen Venegas; Anne Grünewald
Journal:  Front Cell Dev Biol       Date:  2021-11-05

Review 7.  Calmodulin binding proteins and neuroinflammation in multiple neurodegenerative diseases.

Authors:  Danton H O'Day; Robert J Huber
Journal:  BMC Neurosci       Date:  2022-03-04       Impact factor: 3.288

Review 8.  Fisetin as a Senotherapeutic Agent: Biopharmaceutical Properties and Crosstalk between Cell Senescence and Neuroprotection.

Authors:  Osama Elsallabi; Antonia Patruno; Mirko Pesce; Amelia Cataldi; Simone Carradori; Marialucia Gallorini
Journal:  Molecules       Date:  2022-01-23       Impact factor: 4.411

Review 9.  Emerging Potential of Exosomal Non-coding RNA in Parkinson's Disease: A Review.

Authors:  Peng Zhang; Madiha Rasheed; Junhan Liang; Chaolei Wang; Lin Feng; Zixuan Chen
Journal:  Front Aging Neurosci       Date:  2022-03-10       Impact factor: 5.750

Review 10.  Inflammasomes as therapeutic targets in human diseases.

Authors:  Yangxin Li; Hui Huang; Bin Liu; Yu Zhang; Xiangbin Pan; Xi-Yong Yu; Zhenya Shen; Yao-Hua Song
Journal:  Signal Transduct Target Ther       Date:  2021-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.